Tesaro Announces Priority Review Designation for Niraparib NDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
Baird Incrementally Positive on Tesaro (TSRO) After Niraparib NDA Accepted
December 20, 2016 10:21 AM ESTBaird analyst Michael Ulz is Incrementally positive on Tesaro (NASDAQ: TSRO) niraparib NDA acceptance with no AdCom expected.
Ulz commented, "Tesaro announced that the FDA has accepted the niraparib NDA for 2L+ maintenance of ovarian cancer. Importantly, a shorter six month Priority... More

